The Structure For Writing This Is A Bit Weird Because I Have ✓ Solved

The Structure For Writing This Is A Bit Weird Because I Have To Cut Ou

The structure for writing this is a bit weird because I have to cut out and post this onto a poster board for display so the paper has to be written in SECTIONS. APA format: Instructor specified No running header, No title page, No page numbers. I will Obviously have to do the poster board but the paper should be written so I just cut it out and paste it on. Here is what my instructor is looking for on the poster board. Please use the following section headings for your Disease Board: ABOUT THE PATHOGEN Include: Organism’s scientific name Type of organism and morphology VIRULENCE FACTORS TRANSMISSION (& RESERVOIR if appropriate) SIGNS AND SYMPTOMS Include: Incubation period Any complications or sequelae DIAGNOSIS, TREATMENT AND PREVENTION Include: Any drug resistance Vaccine availability and type Remember that the paper you submit in Blackboard should be printed, cut and pasted onto the board into these sections.

Sample Paper For Above instruction

About the Pathogen

The pathogen selected for this board is Mycobacterium tuberculosis, the causative agent of tuberculosis (TB). This bacterium belongs to the genus Mycobacterium, characterized as a slow-growing, acid-fast, rod-shaped bacterium. Morphologically, M. tuberculosis appears as slender, slightly curved rods approximately 2-4 micrometers in length. It is a facultative intracellular pathogen that primarily infects the lungs but can disseminate to other organs.

Virulence Factors

M. tuberculosis possesses several virulence factors that enable it to evade host immune defenses and establish infection. Key factors include the mycolic acid-rich cell wall, which confers acid-fastness and resistance to desiccation; the secretion of ESAT-6 and CFP-10 proteins that modulate immune responses; and the ability to survive within macrophages by inhibiting phagosome-lysosome fusion. These factors collectively contribute to the pathogen's persistence and pathogenicity.

Transmission and Reservoir

The primary mode of transmission is via inhalation of airborne droplets containing M. tuberculosis bacilli expelled when an infected person coughs, sneezes, or talks. The reservoir for the bacteria is humans, as they are the only natural hosts. Transmission is most efficient in crowded and poorly ventilated environments, making TB an airborne disease of significant public health concern worldwide.

Signs and Symptoms

The incubation period for TB ranges from 2 to 12 weeks post-exposure. Symptoms may include persistent cough lasting more than three weeks, hemoptysis, night sweats, weight loss, fever, and fatigue. Complications can include the development of active pulmonary disease, dissemination to other organs leading to miliary TB, and in some cases, drug-resistant TB strains complicating treatment.

Diagnosis, Treatment, and Prevention

Diagnosis of TB involves skin testing (Mantoux tuberculin skin test), interferon-gamma release assays (IGRAs), chest radiography, and microbiological analysis of sputum samples. Drug resistance, particularly multidrug-resistant TB (MDR-TB), is a significant concern, necessitating alternative treatment regimens. Standard treatment includes a combination of antibiotics such as isoniazid, rifampicin, ethambutol, and pyrazinamide, typically over six months. The Bacillus Calmette-Guérin (BCG) vaccine is available and used primarily in countries with high TB prevalence, providing variable protection, especially against severe pediatric forms.

Conclusion

Understanding the biology and transmission of M. tuberculosis is essential for controlling TB outbreaks. Advances in diagnostics and treatment have significantly reduced disease burden, but the emergence of drug-resistant strains highlights the need for continued research and public health initiatives to prevent and treat TB effectively.

References

1. World Health Organization. (2023). Tuberculosis. https://www.who.int/news-room/fact-sheets/detail/tuberculosis
2. Steingart, K. R., Schiller, I., Horne, D. J., Pai, M., Boehme, C. C., Dendukuri, N., & Dheda, K. (2014). Xpert MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance. Cochrane Database of Systematic Reviews, (11), CD009593.
3. Marais, B. J., & Gie, R. P. (2019). Tuberculosis in children. The New England Journal of Medicine, 362(11), 998-1007.
4. Trajman, A., et al. (2010). The tuberculin skin test: an update. Frontiers in Microbiology, 1, 126.
5. Northrup, J. B., & Kelman, M. (2022). Managing drug-resistant tuberculosis: current perspectives. Journal of Infectious Diseases, 225(Supplement_1), S96–S104.
6. Lawn, S. D., & Zumla, A. (2011). Tuberculosis. Lancet, 378(9785), 57–72.
7. Tipple, C., & Bird, T. (2020). Advances in TB diagnostics. Clinical Microbiology Reviews, 33(3), e00054-19.
8. Centers for Disease Control and Prevention. (2022). Mycobacterium tuberculosis (TB). https://www.cdc.gov/tb/topic/basics/default.htm
9. Abdool Karim, S. S., & Abdool Karim, Q. (2013). HIV timebomb: the growing burden of HIV-associated tuberculosis. The New England Journal of Medicine, 368(22), 2144-2147.
10. Joshi, R., et al. (2014). Multidrug-resistant tuberculosis in India: challenges and way forward. Indian Journal of Medical Research, 140(3), 371–382.